What is the level of liabilities of ESSA Pharma this year?
ESSA Pharma has a debt balance of 3.5 M USD this year.
ESSA Pharma Liabilities 2024
ESSA Pharma Liabilities
3.5 M USD
Ticker
EPIX
ISIN
CA29668H7085
WKN
A2JKQ4
In 2024, ESSA Pharma's total liabilities amounted to 3.5 M USD, a 45.63% difference from the 2.4 M USD total liabilities in the previous year.
ESSA Pharma Aktienanalyse
What does ESSA Pharma do?
ESSA Pharma Inc is a biopharmaceutical company specializing in the development of therapies for the treatment of prostate cancer and other types of cancer. The company is headquartered in Vancouver, Canada and was founded in 2009. The history of ESSA Pharma Inc begins with the discovery of a new approach to treating prostate cancer by the company's founders. They discovered that a combination of an androgen receptor inhibitor and a NEDDylation signaling inhibitor could offer a new and effective approach to treating prostate cancer. Based on this discovery, they founded ESSA Pharma Inc to further develop this therapy. ESSA Pharma Inc's business model is based on the discovery, development, and commercialization of therapies for the treatment of prostate cancer and other types of cancer. The company has a pipeline of products in various clinical phases aimed at effectively combating prostate cancer and other types of cancer. ESSA Pharma Inc operates in two main divisions: research and development, and marketing and sales. The company's research and development department is dedicated to identifying and developing new compounds tailored to the specific needs of patients with prostate cancer. The company also works closely with researchers and physicians to test the efficacy of its products in treatment protocols and clinical practice. The second division of ESSA Pharma Inc deals with the marketing and sales of its products. Here, the company works closely with pharmaceutical manufacturers and other companies to market and sell its products worldwide. The company also has its own sales department that serves customers worldwide. ESSA Pharma Inc currently offers several products in different stages of clinical trials. These include EPI-506, an androgen receptor inhibitor currently being used in a Phase 1 study for the treatment of prostate cancer, and EPI-7386, a NEDDylation signaling inhibitor currently in a Phase 1 study for the treatment of prostate cancer. In addition, ESSA Pharma Inc has formed partnerships with other companies to further develop its technology platform and pipeline of cancer therapies. For example, the company is collaborating with Bayer Healthcare to advance the development of EPI-7386. Overall, ESSA Pharma Inc is an innovative and emerging biotech company focused on the development of therapies for the treatment of prostate cancer and other types of cancer. The company is pursuing an ambitious strategy and has already achieved promising results in the development of new compounds for the treatment of prostate cancer. ESSA Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing ESSA Pharma's Liabilities
ESSA Pharma's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating ESSA Pharma's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing ESSA Pharma's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
ESSA Pharma's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in ESSA Pharma’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about ESSA Pharma stock
What were the liabilities of ESSA Pharma compared to the previous year?
The liabilities of ESSA Pharma have increased by 45.63% increased compared to the previous year.
What are the consequences of high debt for investors of ESSA Pharma?
High liabilities can pose a risk for investors of ESSA Pharma, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in ESSA Pharma?
Low liabilities mean that ESSA Pharma has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of ESSA Pharma affect the company?
An increase in liabilities of ESSA Pharma can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of ESSA Pharma affect the company?
A decrease in the liabilities of ESSA Pharma can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of ESSA Pharma?
Some factors that can influence the liabilities of ESSA Pharma include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of ESSA Pharma so important for investors?
The liabilities of ESSA Pharma are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can ESSA Pharma take to modify the liabilities?
To change its liabilities, ESSA Pharma can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does ESSA Pharma pay?
Over the past 12 months, ESSA Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ESSA Pharma is expected to pay a dividend of 0 USD.
What is the dividend yield of ESSA Pharma?
The current dividend yield of ESSA Pharma is .
When does ESSA Pharma pay dividends?
ESSA Pharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of ESSA Pharma?
ESSA Pharma paid dividends every year for the past 0 years.
What is the dividend of ESSA Pharma?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is ESSA Pharma located?
ESSA Pharma is assigned to the 'Health' sector.
Wann musste ich die Aktien von ESSA Pharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of ESSA Pharma from 11/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/24/2024.
When did ESSA Pharma pay the last dividend?
The last dividend was paid out on 11/24/2024.
What was the dividend of ESSA Pharma in the year 2023?
In the year 2023, ESSA Pharma distributed 0 USD as dividends.
In which currency does ESSA Pharma pay out the dividend?
The dividends of ESSA Pharma are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von ESSA Pharma
Our stock analysis for ESSA Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ESSA Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
